A human hormone, rebuilt to last
Native GLP-1 is destroyed within minutes by the enzyme DPP-4. Semaglutide keeps the backbone of that hormone but changes two things: a substitution at position eight that the enzyme cannot cut, and a fatty acid chain attached further along.
That chain binds the peptide to albumin in the blood, which slows clearance dramatically. The result is a molecule with a half-life measured in days rather than minutes, which is what made weekly dosing feasible in the first place.
The design did not arrive from nowhere. An earlier compound in the same family used a shorter fatty acid and a daily interval, and this one is the result of pushing that albumin-binding idea further: a longer linker, a different attachment point, a slower exit. Reading the liraglutide file next to this one shows how incremental the chemistry actually was.
Two systems, one receptor
At the pancreas, GLP-1 receptor activity increases insulin release in a glucose-dependent way, meaning it acts when blood sugar is high and largely stands down when it is not. That dependence is why the class carries a lower hypoglycaemia risk than older insulin secretagogues.
In the brain, receptors in the hypothalamus and brainstem are involved in appetite signalling, and gastric emptying slows. The weight effect in the trials comes from that combination rather than from any single mechanism.
| Class | GLP-1 receptor agonist |
| Backbone | Human GLP-1, modified |
| Key modification | DPP-4-resistant substitution plus fatty acid chain |
| Half-life | Approximately one week |
| Format | Research vial, 5 mg |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Large randomised clinical programme |
| Category | Research use only |
Analytical detail only. It says what the material is, not what it does.
Why the trial record is the point
SUSTAIN covered glycaemic control, STEP covered weight, and SELECT looked at cardiovascular outcomes. Tens of thousands of participants, published protocols, pre-registered endpoints. That is a different category of evidence from almost everything else on this site.
Hold the other compounds here to that standard and most of them come up short, which is exactly the comparison we would rather you made yourself than take our word for.
If you arrived here typing what is semaglutide into a search box, the shortest defensible answer is that it is a modified human hormone carrying the deepest published file of anything in this catalogue. The literature indexed on PubMed is where that depth becomes visible, and it is worth an hour before you accept any supplier’s condensed version of it, ours included.
From the semaglutide vial to the published file
A vial of lyophilised peptide is not a finished preparation, and the distance between the two is where most avoidable problems sit. Dry material is comparatively forgiving; the moment it is in solution the clock starts, and temperature, light and the number of times a stopper is pierced all begin to count against it. Our storage and shelf-life notes set out what changes at that point.
The public conversation about this molecule has travelled a long way from the laboratory. One piece of shorthand now covers several compounds with quite different files behind them, which is why we keep a separate page on the weight-loss injection label. The finished medicines carry marketing authorisations and published assessments, the European assessment report for one of them shows what that review involves, and none of it transfers to laboratory material sold for research.
Semaglutide in the catalogue
Analysed by HPLC to a 99% minimum, with a certificate for every batch.
Where Semaglutide fits in
Three more pages if you want to go further.
About Semaglutide
The questions that come up before an order.